Scroll Down
TICAROS Story
TICAROS Co.Ltd is a biotech company which develops the next generation immunotherapeutics for cancers
Science & Technology
CAR-T
THERAPY
Chimeric Antigen Receptor T cell Therapy : A genetically engineered T cell therapy, in which T cells isolated from the cancer patient are converted into tumor-killing T cells by introducing tumor-targeting antibody-based receptor (chimeric antigen receptor) and are infused back to the patient
MORE VIEW
Science & Technology
CLIP CAR
PLATFORM
CLIP-CAR (Clamping-based Immunological Synapse Potentiating CAR) technology improved CAR-T cell efficacy by stabilizing immune synapse between cancer cells and surface of CAR-T cells through a new CAR backbone structure
MORE VIEW
Science & Technology
CONVERTER
CAR PLATFORM
CTLA-4, an immune checkpoint receptor, is selectively inhibited in tumor-specific T cells to potentiate its anti-tumor activity without autoimmune adverse side effects
MORE VIEW
PIPELINE
IMMNUNO-ONCOLOGY
TICAROS proposes a new treatment option using cutting-edge technology in immunology and antibody-engineering
We develop best-in class, first-in class therapies based on Converter CAR platform for better T cell
activity and on CLIP CAR platform for more stable immune synapse of CAR-T cells
TICAROS
News and PR
.png)
TiCARos Submits IND to MFDS for Phase 1 Solid Tumor Trial of MUC1 CAR-T
TiCARos Submits IND to MFDS for Phase 1 Solid Tumor Trial of MUC1 CAR-T Bas
2026-10-14
.png)
TiCARos Recognized with Award at CAR-TCR Summit in the U.S., Highlighting Innovation of Its CAR-T Platform
TiCARos Recognized with Award at CAR-TCR Summit in the U.S., Highlighting Innov
2026-10-14
.png)
TiCARos Receives Dual “A” Ratings in Technology Assessment for KOSDAQ Listing, Underscoring Strength of Its CAR-T Platform
TiCARos Receives Dual “A” Ratings in Technology Assessment for KOSDAQ Listing,
2026-10-14